➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Mallinckrodt
Johnson and Johnson
Medtronic
Dow

Last Updated: September 22, 2020

DrugPatentWatch Database Preview

Patent: 9,725,444

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,725,444
Title:Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases
Abstract: Compounds as inhibitors of CSCPK and related kinases. The compounds are thiazole-substituted indolin-2-ones and are prepared from indolin-2-ones. They are included in pharmaceutical compositions and both the compounds and the pharmaceutical compositions are used in inhibiting cancer stem cells and in the treatment of a protean kinase related disorders.
Inventor(s): Li; Chiang Jia (Cambridge, MA), Liu; Ji-Feng (Winchester, MA), Li; Youzhi (Westwood, MA), Li; Wei (Wayland, MA), Rogoff; Harry (Wrentham, MA)
Assignee: BOSTON BIOMEDICAL, INC (Cambridge, MA)
Application Number:14/445,783
Patent Claims:see list of patent claims

Details for Patent 9,725,444

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial BOSTON BIOMEDICAL, INC (Cambridge, MA) 2039-02-26 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Start Trial BOSTON BIOMEDICAL, INC (Cambridge, MA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial BOSTON BIOMEDICAL, INC (Cambridge, MA) 2039-02-26 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial BOSTON BIOMEDICAL, INC (Cambridge, MA) 2039-02-26 RX Orphan search
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial BOSTON BIOMEDICAL, INC (Cambridge, MA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
McKesson
Boehringer Ingelheim
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.